XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Xenetic Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.93−0.06 (-3.02%)
Close on Oct 19, 2026
- Market cap
- $4.43M
- P/E (TTM)
- –
- Dividend yield
- –
Xenetic Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q3 25 | Q2 25 | Q1 25 | Q3 24 | Q2 24 | Q1 24 | Q3 23 | Q2 23 | Q1 23 | Q2 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Revenue [Member] | $660.60K | $806.92K | – | $589.90K | $593.26K | – | – | – | – | – | – | – | 100.0% | +12.0% |
| Collaborative Agreements [Member] | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Xenetic Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.